source
- BioNTech-Genentech halts colorectal cancer vaccine trial after higher death rate in vaccine armBioNTech and Genentech stopped a phase 2 trial of their personalized mRNA vaccine BNT122 in patients with stage 2 or 3 colorectal cancer after an independent data safety monitoring board found more…
- Moderna's cancer vaccine boost lifts stock, sparks talk of Keytruda-like reachModerna’s shares surged 177% after a phase 3 topline win for its Merck‑partnered cancer vaccine, intismeran autogene, was disclosed. The data, released on Wednesday, added roughly $45 billion to Mo…